Consumer Choice and FDA Regulation of Sunlamp Products by Shaltz, Faina
 
Consumer Choice and FDA Regulation of Sunlamp Products
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Faina Shaltz, Consumer Choice and FDA Regulation of Sunlamp
Products (2011).
Accessed February 19, 2015 9:21:12 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965637
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAConsumer Choice and FDA Regulation of Sunlamp Products 
Abstract 
This paper explores the history of FDA regulation of sunlamps since 1974, identifies and 
critiques the overriding rationale of consumer choice as the background for relatively lax 
FDA regulations, and discusses the possible ways in which FDA regulation of sunlamps can 
change to better suit the FDA’s role in protecting consumers from dangerous products. 
Proposals for sunlamp regulation are identified and analyzed, leading to the conclusion 
that more effective regulation of sunlamp use requires at least some abandonment of the 
consumer choice rationale in sunlamp regulation. 
 
Introduction 
 “The United States Department of Health and Human Services and the World Health 
Organization’s International Agency for Research on Cancer have classified UV radiation 
from tanning devices as carcinogenic to humans, in the same category as tobacco and 
tobacco smoking. A review of seven studies found a 75 percent increase in melanoma in 
those who had been exposed to UV radiation from indoor tanning before the age of 35.”1 
 
“You might be surprised at the number of benefits of tanning beds. Obviously, the most 
obvious benefit is developing a wonderful tan. Typically, as summer approaches, people 
will begin to visit the local tanning salon to establish a base tan so when they do go 
outdoors in the sun they do not burn, or to develop a rich tan that looks as if they just came 
                                                        
1 American Academy of Dermatology and AAD Association. Position Statement on Indoor 
Tanning, November 14, 2009. Available: www.aad.org/.../Position%20statements/PS‐
indoor‐tanning.pdf.  back from vacation in Hawaii. Then, there are other individuals who have a special function 
to attend whereby they want a healthy glow.”2 
 
 “While indoor tanning is a cosmetic service, a well‐known side effect of exposing the skin 
to ultraviolet (UV) light is the production of vitamin D. Emerging evidence suggests that 
there may be an epidemic of vitamin D deficiency in North America. Research also suggests 
that vitamin D plays an important role in maintaining good health.”3 
 
“[A] common misperception is that indoor tanning protects you from sun damage by  
providing a base tan, and can be a safe source of vitamin D. Both are false.”4 
 
 “[T]he agency believes that sunlamps perform a function desired by the consumer and, 
consequently, has not penalized the prudent individual by removing this potentially 
hazardous product from the marketplace.”5 
 
“If you’re confused about the health effects of indoor tanning, rest assured: You’re not 
alone. For decades, the American Academy of Dermatology, the Skin Cancer Foundation, 
and other medical groups have pounded home the message that it’s a dangerous practice 
and should be avoided. Many dermatologists suggest that the tanning industry, like the 
                                                        
2 Tanning Info Center. The Benefits of Tanning Beds. Available: 
http://www.tanninginfocenter.com/benefits‐of‐tanning‐beds.html.  
3 The Indoor Tanning Association. “Positive Effects of UV Light.” Available: 
http://www.theita.com/?page=Positive_Effects_UV. 
4 McCook, Alison. “Many ignore indoor tanning risks.” Reuters, 2010. Available: 
http://www.reuters.com/article/2010/12/21/us‐indoor‐tanning‐
idUSTRE6BK44L20101221.   
5 21 CFR §1002 (1985). tobacco industry before it, is manipulating and distorting scientific evidence to protect a 
dangerous product.”6 
 
  There is little question that UV exposure is carcinogenic. Sunlamps emit ultraviolet 
radiation in selected wavelengths. Though also used therapeutically, sunlamps are 
associated with indoor tanning and the cosmetic effect of darker skin that UV exposure 
causes. Since the advent of sunlamps and their growing popularity in the United States, the 
risks posed by UV radiation can be accessed via indoor tanning facilities. This paper 
explores FDA regulation of sunlamps used for cosmetic purposes, and questions the 
validity of consumer choice as a rationale for allowing their continued existence on the 
market. Part I presents a history of FDA regulation of sunlamps from 1974 to the present 
day, and concludes that little about their regulation has changed since sunlamps entered 
the market. FDA regulation has continued to focus on labeling requirements with the goal 
of informing consumers about the dangers of sunlamps to enable them to make informed 
choices about their use. Part II discusses the scientific evidence pertaining to the dangers of 
sunlamp use. Sunlamps emit UV radiation, which damages skin and causes DNA mutation 
of subcutaneous cells. These mutations in turn lead to the development of cancerous cells. 
Part III introduces state regulations pertaining to sunlamp use, showing that states’ 
emphasis is on the appropriate age to begin tanning. States’ responses to the dangers of 
tanning show that there is a still an important role for the FDA to play in protecting 
consumers from dangerous products. Though age‐based restrictions are an important step 
                                                        
6 Voiland, Adam. “The Indoor Tanning Industry Wants You.” US News Health, 2008. 
Available: http://health.usnews.com/health‐news/family‐
health/articles/2008/06/25/the‐indoor‐tanning‐industry‐wants‐you.  in ensuring that consumers of sunlamps have the maturity necessary to balance the risks 
and benefits of indoor tanning, consumer confusion still abounds and FDA action is sorely 
needed. Part IV discusses the tax on indoor tanning levied by §10907 of the Patient 
Protection and Affordable Care Act (PPACA). The tax’s effect remains to be seen, but it 
appears a step in the direction of incentivizing consumers to reconsider the desirability of 
indoor tanning. PPACA’s mention of indoor tanning indicates an acknowledgment by our 
federal government of the dangers posed by indoor tanning, and suggests that avenues 
outside of the FDA are also available for protecting consumers from the dangers of sunlamp 
use. Part V discusses potential avenues for future FDA regulation of sunlamps, concluding 
that reclassification of sunlamps as Class II Medical Devices would constitute an important 
move by the FDA in reducing consumer use of sunlamps. Part VI weighs concerns about 
governmental paternalism with the value of consumer choice, concluding that the FDA’s 
role in balancing these values requires more weight in favor of protection of consumers. 
Part VII surveys several recent court cases pertaining to injuries from sunlamp use, and 
considers lessons these cases may provide for advocates of consumer choice. Ultimately, 
the dangers of sunlamps are serious, and this paper concludes that more stringent 
regulation of the indoor tanning industry by the FDA is necessary. 
 
I. History of Sunlamp Regulation by the FDA 
   Despite continuing recognition of the dangers of indoor tanning, the FDA has chosen 
to allow the use of sunlamps for cosmetic purposes, citing the importance of consumer 
choice. Since the FDA began its regulation of sunlamps, it has focused upon ensuring that 
these devices are accompanied by information that should permit the reasonable consumer to make a decision regarding the risks and benefits of sunlamp use. Sunlamps first made 
their appearance in Europe in the 1970s as winter‐weary individuals sought an alternative 
to natural sunlight7. In the 1970s, indoor tanning made its way to the United States and 
gained popularity.8   
The FDA first began to tackle regulation of  “sunlamps” in 1974, at which time it was 
already known that indoor tanning carried risks to skin health. In 1974, sunlamp makers 
were required to report injuries caused by the use of sunlamps9, but the FDA requested 
more information about the risks that they posed to the consumer.10 Acknowledging the 
“potential hazard” posed by sunlamps, the FDA opened the topic of sunlamp regulation to 
notice and comment. While the carcinogenic nature of tanning was as yet unknown in 
1974, serious injuries from the use of sunlamps had already been reported, such as severe 
burns and retinal damage. In 1975, the FDA invited comments on a wider range of 
questions related to sunlamps. Considering rulemaking on sunlamps, the FDA inquired as 
to what class of products sunlamps should fall into, the sort of performance standard that 
should be instituted for sunlamps, whether sunlamps should be usable in household 
sockets, the health risks posed, the constitution of future warning labels, and the 
environmental effects of sunlamps. Also in 1975, the FDA distinguished sunlamps used in 
the healthcare setting, defining its regulation as applying only to those sunlamps used 
without the aid of a physician or physical therapist.11  
                                                        
7 Drummond, Katie. “Indoor Tanning Gets a Moment in the Sun. March 29, 2010. Available: 
http://www.aolnews.com/2010/03/29/indoor‐tanning‐getting‐unwanted‐moment‐in‐
the‐sun/ 
8 Id.  
9 21 C.F.R. § 1002 (1974). 
10 Id. 
11 21 C.F.R. §1020 (1975).   The first comprehensive regulation of sunlamps by the FDA was proposed in 1977 
and was “intended to reduce the possibility of sunlamp‐related injury by reducing 
unnecessary exposure and overexposure to sunlamp radiation.”12 In the years intervening 
since the FDA first recognized the need to regulate sunlamp exposure, the National 
Electronic Injury Surveillance System, run by the Consumer Product Safety Commission, 
had estimated that sunlamps caused thousands of injuries per year resulting in visits to the 
emergency room.13 The first tests on laboratory animals exposed to sunlamps had also 
yielded results suggesting that sunlamps may cause skin cancer.14 Though tests on 
laboratory animals are not conclusive evidence of a device’s effects on humans, in the case 
of sunlamps ethical considerations dictate the impossibility of conducting human trials. 
Nevertheless, given the scientific community’s understanding of UV radiation’s effect on 
skin and the results of such animal studies, it is safe to conclude that the current state of 
scientific understanding leaves little doubt that UV radiation from sunlamps poses serious 
danger to the skin of consumers. 
In responding to the concerns raised by such reports, the FDA Commissioner could 
have taken one of a number of courses of action. As described in the 1977 proposed rule, 
the Commissioner could have used the defect provisions of the Public Health Service Act, 
set forth voluntary recommendations for sunlamp makers, or created a product 
performance standard. Examining these options, the Commissioner found that using defect 
provisions would be problematic because they are not prospective, and voluntary 
                                                        
12 21 C.F.R. §1040 (1977). 
13 Id. 
14 Id. recommendations lack the enforcement ability of performance standards.15 The defect 
provisions of the Public Health Service Act would essentially have allowed the 
Commissioner to claim that sunlamps possess a defect that makes them ineligible for sale 
in the United States. Conceivably that defect could be carcinogenicity or general impact on 
skin health. Voluntary recommendations would permit the FDA to give the tanning 
industry flexibility in meeting the suggestions by the FDA, but since enforceability is 
important when protecting the safety of consumer products the advantage of voluntary 
recommendations over product performance standards is slim.  Settling on the use of 
“mandatory product performance standards,” the Commissioner acknowledged that this 
route would not mitigate all risks from sunlamps, and that the FDA was open to the 
possibility of stronger consumer protection, more comprehensive use restrictions, and 
even banning the use of sunlamps outside the prescription setting.16  
  The first final rule regarding sunlamps was promulgated in 1979. In addition to 
setting forth a performance standard for the use of sunlamps in the United States, in the 
Federal Register the FDA considered and responded to comments made regarding the 
proposed rule. Ultimately, though the FDA acknowledged the risks posed by sunlamp use, it 
concluded that “sunlamps perform a function desired by the consumer, and consequently, 
has not penalized the prudent individual by removing this potentially hazardous product 
from the marketplace.”17 Essentially, the FDA’s regulation of sunlamps appears to have 
started from the premise of guarding consumer choice. The 1979 regulations defined 
sunlamps as a medical device, because the FDA believed the therapeutic function of 
                                                        
15 Id. 
16 Id. 
17 21 C.F.R. §1002 (1979). sunlamps for use in treating disorders like psoriasis could not be readily separated from 
the cosmetic use of the product.18 In order to protect consumers in both therapeutic and 
cosmetic contexts, the FDA decided to promulgate performance standards for sunlamps 
generally as a medical device. The question of distinguishing between therapeutic and non‐
therapeutic uses of sunlamps presented an issue of contention, and the FDA also indicated 
in 1979 that its regulations were meant to apply only to sunlamps meant for cosmetic use, 
presumably under the assumption that therapeutic uses of sunlamps would include 
physician supervision and therefore that consumers in that setting do not need the same 
protections. However, in 1979 the FDA also acknowledged, “there may be no safe threshold 
level for exposure to ultraviolet radiation.”19 The FDA initially got involved to ensure the 
safety of sunlamps used in the United States, but from the inception of the FDA’s regulation 
of sunlamps the emphasis has been on consumer choice.  While recognizing the known 
dangers of sunlamp use, the FDA’s focus was almost exclusively on labeling requirements 
designed to inform the consumer.  Some regulations of the actual use of sunlamps were 
also promulgated in 1979, such as a ten‐minute maximum for exposure, and requirements 
for the use of protective eyewear. The bulk of the 1979 rules were dedicated, however, to 
ensuring that adequate labeling informed the consumer of the dangers of sunlamp use. The 
tanning industry balked at the labeling regulations, arguing in a comment that the FDA 
does not require labels as comprehensive on cigarettes, which are known to be dangerous 
to human health. Sidestepping the comparison, the FDA simply indicated that cigarettes 
were not the subject of the particular regulation at issue.  
                                                        
18 Id. 
19 Id.   Since the 1979 regulations, sunlamp performance standards have changed 
minimally to accommodate changes in sunlamp technology and the development of new 
sunlamp products. The wavelength range of light for which the sunlamp regulations apply 
has been changed, from 180‐320 nm to 200‐400 nm, in keeping with the changing 
wavelength coverage of new sunlamps.20  The FDA also changed the applicability of its 
regulations to sunlamps that emit UVA (as opposed to UVA and UVB) radiation.21 
Additionally, the FDA altered the warning labels, requiring a statement that individuals that 
do not tan easily in natural sunlight are unlikely to achieve the desired cosmetic tanning 
effect from the use of sunlamps.22  
  The current FDA stance on sunlamps intended for cosmetic purposes defines 
sunlamps as a Class I Medical Device, the least regulated category for medical devices. In 
March 2010, the FDA convened its Advisory Committee to consider changes to its rules 
regarding sunlamps. While the option of reclassifying sunlamps as Class II medical devices, 
thus strengthening the restrictions on their marketing and use, was on the table, the FDA 
concluded in May 2010 that they would remain Class I devices but that warning labels 
should be strengthened. The FDA filed a report with Congress in response to a mandate 
from 2007, elucidating the need for clearer warning labels and better positioning for the 
labels. The FDA consulted focus groups to determine the most effective way to 
communicate risks of indoor tanning to consumers. Through a number of rulemakings, 
however, the FDA’s classifications and requirements for sunlamps have essentially 
                                                        
20 21 C.F.R. §1040 (1985). 
21 Id. 
22 Id. remained unchanged: with adequate labeling and a few other restrictions, the FDA allows 
consumers to use sunlamps at will.  
 
II. Dangers of Sunlamp Use 
  The risks posed by UV light are well‐documented, and links have been made 
between sunlamp use and the likelihood of developing melanoma and other skin 
diseases.23 Since 1974, more and more information has been gathered indicating the risks 
associated with use of sunlamps, and several advocacy organizations have requested that 
the FDA change its permissive stance toward sunlamps. In 1992, the International Agency 
for Research on Cancer released its review of evidence regarding the dangers of sunlamp 
use. It concluded that radiation from sunlamps is strongly linked to skin cancer, 
particularly melanoma.24 A recent study in Pediatrics provides an overview of the 
scientifically known risks of sunlamp use to date, and the results are grim. Not only do 
animal studies show that UV light possesses carcinogenic properties25, but UV light is also 
known to cause sunburn, skin damage, skin aging, and photosensitivity.26  Exposure to UV 
light has been linked to many serious skin problems, from photoaging to age spots to 
                                                        
23 American Academy of Dermatology. “Indoor Tanning.” Available: www.aad.org/media‐
resources/stats‐and‐facts/prevention‐and‐care/indoor‐tanning.  
24 International Agency for Research on Cancer. IARC Monographs on the Evaluation of 
Carcinogenic Risks to Humans. Volume 55: Solar and Ultraviolet Radiation. Summary of 
Datae Reported and Evaluation. Geneva, Switzerland: World Health Organization; 1997. 
Available at: http://monographs.iarc.fr/ENG/Monographs/vol55/volume55.pdf. Accessed 
April 20, 2011.  
25 Balk, Sophie and the Council on Environmental Health and Section on Dermatology. 
“Technical Report Ultraviolet Radiation: A Hazard to Children and Adolescents.” Pediatrics, 
Feb. 28, 2011, pg. e794. 
26 Id at 793‐794 multiple forms of skin cancer.27 UV radiation has specifically been shown to cause cancer 
through its effects on skin’s cellular DNA. Absorption of UVA and UVB light by the skin’s 
layers leads to genetic mutations that are known to cause cancer.28 UVB light absorbs into 
fewer layers of human skin, and is thus less likely to be carcinogenic than UVA light. 
Unfortunately, sunlamps are manufactured to primarily emit the more dangerous UVA 
radiation.29  
Figure 1: Absorption of UVA and UVB light by the skin.30 
 
 
The cosmetic effect of tanning actually signals that the skin has experienced damage as a 
result of UV radiation. Skin becomes darker in response to UV exposure in an attempt to 
protect its DNA from further injury. Essentially, DNA in the skin mutates in order to protect 
                                                        
27 “UV Skin Damage in a Different Light. NIH, 1998. Available: 
www.nih.gov/news/pr/aug98/nigms‐31.htm.   
28 “UV Information.” www.skincancer.org/understanding‐uva‐and‐uvb.html.  
29 Id. 
30 Id. itself, and these mutations are known to cause various forms of skin cancer.31 Tumors 
eventually grow on the skin as a result and commonly known symptoms such as moles or 
discolorations occur on the skin. 
 
Figure 2: Growth of tumor cells on the skin.32 
 
  The effects of UV light on skin can be mitigated through the use of sunscreen 
products and by avoiding direct exposure to the sun; however, the use of sunlamps 
increases individuals’ normal exposure to UV radiation and thus the risk of developing skin 
cancer. The cosmetic effects promised by the tanning industry, darker skin as a result of 
using sunlamps, appears to be directly related to the development of cancerous skin cells.  
  Given the wealth of scientific evidence regarding the dangers of sunlamp use, it 
seems antithetical to the FDA’s role in our government that regulation of sunlamps is so lax. 
UV light, upon contact with skin, essentially sets off a carcinogenic process that leads to 
                                                        
31 Id. 
32 Id. dangerous skin disorders. Given such a strong causal link between exposure to UV light and 
cancer, it is surprising that the FDA has not taken a more active role in mitigating or 
removing this danger from the market. Sunlamps have been likened to cigarettes in their 
carcinogenic quality, but one key distinction may serve to explain the FDA’s reticence in 
restricting access to sunlamps: unlike cigarette use, even those who do not use indoor 
tanning facilities are exposed to damaging UV light. Sunlamps, as per their name, are meant 
in many respects to mimic the effects of the sun. Though rates of skin cancer have 
increased dramatically since sunlamps entered the market, exposure to the carcinogenic 
UV light they emit occurs naturally as well.  Nevertheless, given the controlled nature and 
increased intensity of UV light emitted by sunlamps, data on the effects of UV exposure on 
skin is very relevant to determining the safety of sunlamps and indoor tanning.  Those who 
are exposed to UV light through nature can take steps to protect themselves: sun block, 
hats, and shade are common options. However, those who consume indoor tanning 
services are seeking out exposure to the harmful rays that science has shown are likely to 
cause cancer. 
 
III. State Regulation of Sunlamps 
  Many states have taken steps in addition to those taken by the FDA to ensure 
consumer safety in the realm of sunlamp use. These regulations restrict or ban use of 
sunlamps by minors, though no state has enacted an outright ban on sunlamp use, nor have 
restrictions based on skin sensitivity, etc. been introduced. One interesting step taken by 
several states has been to ban indoor tanning by minors without a physician’s prescription. 
Taking the decision out of minors’ hands is not a particularly new idea‐ we do this with other substances such as alcohol and tobacco; however, requiring a physician’s approval 
for indoor tanning essentially removes the option of tanning for cosmetic purposes by 
minors. This additional step toward protecting minors from unnecessary UV exposure 
could potentially form a basis for future regulation by the FDA for all consumers.  Requiring 
a physician’s prescription constitutes a paternalistic policy in this area, and would be out of 
keeping with the FDA’s current permissive stance on sunlamp use, but could be a policy 
considered if the FDA reconsiders its regulation of sunlamps.  
Figure 3: Current and Pending State Regulations of Sunlamp Use by Minors33 
Arkansas  Parental signature required under 18. 
Arizona  Written parental permission required under 18. 
California  No tanning for children under 14, and under 18 a parental signature is required. Pending 
state legislation would ban tanning for all minors. 
Connecticut  Written permission from a parent required under the age of 18. Pending legislation would 
require that parent accompany the child for each tanning session. 
Delaware  No tanning for children under 14, and parental signature as well as presence required for 
those under 18.  
Florida  Not tanning for children under 14, and written parental permission required under 18.  
Georgia  No tanning for children under the age of 14, and written parental permission required for 
those under 18.  
Illinois  No tanning for children under the age of 14, parental consent required under the age of 17. 
Pending legislation would extend the tanning ban to anyone under 18. 
Iowa  Pending legislation would require physician’s prescription for those under 18.  
Indiana  Children under 16 must be accompanied at facility by a parent. Parental signature of 
waiver at tanning facility required under the age of 18.  
Kentucky  Children under 16 must be accompanied by a parent, and parental waiver must be signed 
for those under 18 (waiver is valid for one year after signature). Pending legislation would 
prohibit those under 14 from tanning. 
Louisiana  Children under 14 must be accompanied by a parent, and written parental consent is 
required for those under 18.  
Maine  No tanning for children under 14, and those from 14‐15 must be accompanied by a parent. 
Parental consent required for those under 18 (consent valid for one year). Statute 
explicitly requires presenting parents with materials that warn about the risks of indoor 
tanning.  
Maryland  Parental consent, given at tanning facility, required for those under 18. Pending legislation 
would ban minors from using indoor tanning facilities. 
Massachusetts  Parental consent required between the ages of 14 to 17. No tanning for those under 14. 
Pending legislation would ban indoor tanning for those who are under the age of 16. 
Michigan  Parental consent and acknowledgement of dangers of tanning required for those under 18.  
Minnesota  Parental signature on warning statement required for those under 16. Pending legislation 
                                                        
33 “Tanning Restrictions for Minors‐ A State‐by‐State Comparison.” Aim at Melanoma. 
Available: http://www.aimatmelanoma.org/aim‐for‐a‐cure/legislative‐accomplishments‐
in‐melanoma/tanning‐restrictions‐for‐minors.html. would ban tanning under the age of 18 without physician’s prescription.  
Mississippi  Written parental consent required for those under 18.  Consent valid for a year, but must 
indicate the number of sessions it is valid for. 
Missouri  Several pending pieces of legislation would prohibit tanning under the age of 16 and 
require parental presence at the tanning facility for those under the age of 18.  
Nevada  Pending legislation would require written parental consent for those under 18. 
New 
Hampshire 
Physician approval required under the age of 14, and parental consent and accompaniment 
required under the age of 18.  
New Jersey  No tanning for children under the age of 14. Parental consent required for those under 18. 
Pending legislation prohibits tanning for those under 18 altogether. 
New Mexico  Pending legislation bans those under 18 from indoor tanning. 
New York  No tanning for children under 14. Parental consent, given in writing and in presence of 
tanning facility operator, required for those under 18. Consent valid for one year from date 
of signature. Several pieces of pending legislation would either prohibit tanning for those 
under 16 or those under 18. 
North Carolina  No tanning under the age of 13 without physician’s prescription.  Pending legislation 
would raise the age for indoor tanning to 18. 
North Dakota  No tanning without physician’s prescription for those under 14. Signed parental consent 
required for those under 18, valid for one year. 
Ohio  Parental consent before every tanning session required for those under 18.  Pending 
legislation requires physician’s prescription for use of a tanning bed by those under 18. 
Oregon  Parental consent required under the age of 18, signed in the presence of tanning facility 
operator. 
Pennsylvania  Two pieces of pending legislation. One would require a physician’s prescription for those 
under 18, and the other would prohibit tanning for those under 14 without a doctor’s 
prescription and would require parental accompaniment for those under 18. 
Rhode Island  Parental consent form required for those under 18. Pending legislation would require 
physician’s prescription for those under 18. 
South Carolina  Written parental permission required, given in the presence of a tanning facility operator. 
South Dakota  Pending legislation would require parental consent under the age of 18. 
Tennessee  Parental consent required for those under 18. Must be notarized. 
Texas  Parental consent required for those under 18. 
Utah  Parental consent and presence at first tanning session and once every 12 months 
thereafter required for those under 18. 
Vermont  Pending legislation would ban use of indoor tanning under the age of 18. 
Virginia  Written parental consent required under the age of 15. Parents must also indicate their 
child’s skin type. Valid for 6 months. 
Washington  Two pieces of pending legislation would require a physician’s prescription for those either 
under the age of 16 or the age of 18. 
West Virginia  Pending legislation would require parental accompaniment for those under 14 and written 
parental consent for those under 18. 
Wisconsin  No tanning for those under the age of 16. 
Wyoming  Parental consent, signed in presence of tanning facility operator, required for those under 
18. Consent valid for one year. Children under 15 must be accompanied by a parent during 
every visit.  
 
 
 
 IV. PPACA Tanning Tax 
  The Patient Protection and Affordable Care Act (PPACA), Section 10907, imposes a 
10% excise tax on the use of tanning beds34. The tax must be paid by consumers of indoor 
tanning services, and is expected to reduce profits for the tanning industry. The joint goals 
of the tax are to encourage people to make safer decisions about tanning and to help pay 
for other measures in the Act. Since the tax became law in July 2010, indoor tanning 
facilities must charge an additional 10% of their regular rates to clients. From an economic 
perspective, it seems that an incentive is being put in place to move consumers in the 
direction of less tanning.  The effect of this tanning tax on consumption of indoor tanning 
services remains to be seen. Ten percent may not be high enough to deter those who wish 
to secure the cosmetic effects provided by indoor tanning, but it seems a step in the 
direction of more aggressive consumer protection. Consumers are still allowed choice in 
the tax scenario, but the tanning tax makes a move away from the FDA’s emphasis on 
consumer choice. Though not coercive in the sense that the tax does not ban access to 
tanning services, it is at least slightly paternalistic given that PPACA’s drafters have 
identified a consumer activity they believe is unhealthy and have aimed taxation at that 
activity in the hopes of incentivizing safer choices.  
 
V. FDA Options for Regulation of Sunlamps 
  Regulation by states and the federal government through legislation outside the 
scope of the FDA may serve to enhance consumer safety in sunlamp use, but the FDA still 
has a continuing obligation to ensure the safety of consumer products that fall within its 
                                                        
34 U.S. Department of the Treasury, Internal Revenue Service, “Indoor Tanning Services; 
Cosmetic Services; Excise Taxes,” 75 Federal Register 33740, June 15, 2010. purview. These other options for regulating and discouraging sunlamp use by consumers 
may or may not be effective, but the question remains as to the proper role that the FDA 
should play in their regulation. Recent reports on FDA’s activity in the area of sunlamp 
regulation show willingness to consider more intrusive regulations, but recent regulations 
have fallen on the side of favoring consumer choice over consumer protection. The 
majority of FDA regulation throughout the history of sunlamp use in the United States has 
focused on the promulgation of labeling requirements that disclose the dangers of tanning, 
and suggested duration and frequency of exposure. In seeking to protect consumer 
autonomy, it seems that the FDA has forsaken the possibility of more aggressive measures. 
Given the popularity of indoor tanning, it seems likely that warnings alone will not deter 
those who wish to secure the cosmetic effects of sunlamp use.  
  When deciding how to classify sunlamps, the FDA Commissioner faces a number of 
options. Banning sunlamps outright has always been an option, but one the FDA has shied 
away from on consumer choice grounds. Given their dangerous nature, the FDA could also 
have classified sunlamps as Class II or Class III medical devices. The standard for classifying 
a device as Class II or III is based on the dangerousness of the device at issue and the extent 
of scientific knowledge as to the danger that the device poses to the consumer. Since 
sunlamps cannot directly be tested on humans due to research ethics concerns, the 
knowledge regarding their effects is either anecdotal or based on animal studies. Animal 
studies have shown links between exposure to UV radiation and skin cancer, and though 
the FDA has recognized causal links between sunlamp use and melanoma, it has persisted 
in taking a relatively hands‐off approach to regulation in this area.    If the FDA were to entertain stricter regulations on sunlamps, a number of 
important revisions in current law seem in keeping with the need to protect American 
consumers. First, federal age limits on sunlamp use would respect the consumer choice 
rationale the FDA has espoused in this area while ensuring that young users do not 
endanger their health. As a society, we have accepted that individuals under the age of 
eighteen have not matured enough to make decisions such as who to vote for, whether to 
smoke cigarettes, and whether to drink. By extension, it seems we have determined that 
the balancing of risks and benefits expected of adults cannot also be expected of minors; 
therefore, the consumer choice rationale does not apply to them. At the least, requiring 
parental consent for use of sunlamps would ensure that the risks have been adequately 
taken into account by and individual responsible for the minor. Second, reclassification of 
sunlamps as Class II or Class III medical devices would put the tanning industry on notice 
that more than labeling and nonintrusive usage requirements would emerge from future 
FDA regulation. While individuals who use tanning booths are required to cover their eyes 
and there are time limits on sunlamp use, they are otherwise left to their own devices 
regarding sunlamp use. It is, of course, questionable as to whether a balance between more 
regulation and consumer choice can be struck. If sunlamp use is carcinogenic, after all, it is 
possible that the FDA should outlaw their use altogether.  It would not be feasible to 
maintain records of consumers’ sunlamp use to ensure that they do not exceed a certain 
number of uses in a week, but perhaps individual tanning establishments could be required 
to establish limits on the use of their patrons. Third, requiring a physician’s prescription 
may provide an avenue for regulation of sunlamps that does not completely outlaw their 
use. While an accepted method used by states for restricting minors’ use of sunlamps, a prescription requirement would likely destroy the indoor tanning industry. Given the 
dangers of UV light, it is unlikely that physicians would be eager to help their patients gain 
access to such services. If prescription requirements would effectively constitute an 
outright ban, the FDA may not be willing to go that far.  
 
VI. Paternalism and Consumer Choice 
  The line between paternalism and the protection of consumers is rarely clear, but in 
the case of sunlamps it does not seem that the FDA has even come close to toeing that line. 
In its 1985 regulation setting a performance standard for sunlamps, the FDA identified the 
need to “protect the consumer from sunburns… and from exposure to hazardous radiation 
that is unnecessary for skin tanning,” but concluded, “FDA believes that the user of a 
sunlamp can take appropriate action when informed of the possible adverse effects to the 
body from exposure to ultraviolet radiation, if the product is equipped with necessary 
safety performance features.” Despite acknowledging the dangers posed to users of 
sunlamps for cosmetic purposes, the FDA’s 1985 regulation dealt minimally with safety 
features of sunlamp use (focusing on eye protection and time limits for tanning), and 
focused on the labeling requirements for sunlamp products.35 The FDA’s original role in 
government focused on identifying adulterated or inaccurately labeled products. In that 
role, analysis of risks and benefits plays only a minor part; however, with the expansion of 
the FDA’s purview to a variety of drugs and devices the “agency increasingly is required to 
determine the level of risk acceptable in products that are properly manufactured and used 
                                                        
35 Sunlamp Products; Performance Standard. 50 Fed. Reg. 36548 (September 6, 1985).  as intended.”36 The expanded role of the FDA since 1938 requires the agency’s priorities to 
shift, and cost‐benefit analyses of products entering the market are likely to increase in 
importance. In the case of sunlamps, there is little question that their use poses dangers to 
the consumer. Cosmetic benefit in the form of darker skin seems to pale in comparison to 
melanoma, premature aging, and skin discoloration. While the tanning industry insists that 
its products are safe for consumption, the FDA’s role should be to look at such claims 
skeptically and consider whether the average consumer can make appropriate choices 
regarding the health of their skin. Given the continuing popularity of indoor tanning as well 
as the epidemic proportions of skin cancer diagnoses, it seems that a new balance should 
be struck.  
  How strong is the apparent reasoning for the FDA’s decision to leave sunlamps 
accessible to consumers? If no safe level of sunlamp exposure exists, then would a 
reasonable and informed consumer ever choose to use sunlamps? Consumer choice is an 
important value, as we would all like to feel that we have control over what products we 
use, as well as over the risks we decide to take. If indoor tanning can be construed as an 
informed choice by the consumer to accept risks in favor of cosmetic benefits, as the FDA 
has treated it, then it does not seem particularly problematic to keep sunlamps minimally 
regulated. If, however, it could be argued that consumers do not have all the facts about 
sunlamps’ dangers, then more stringent FDA regulations would be in order.  The 
carcinogenic effects of UV exposure are now well known, so it is conceivable that the FDA’s 
position on sunlamp regulation reflects a belief that consumers have weighed the pros and 
cons of indoor tanning and those that choose to use sunlamps do so with their eyes open 
                                                        
36 Richard A. Merrill, Risk­Benefit Decisionmaking by the Food and Drug Administration. 45 
George Washington Law Review 994 (1977).  (figuratively speaking). Nevertheless, it could also be argued that if the carcinogenic effects 
of exposure to UV radiation are truly so well‐known, then it is antithetical to the FDA’s role 
as a gatekeeper for deciding which substances are too dangerous for human consumption 
to allow sunlamps to continue to permeate the market with so little regulation. Just as the 
FDA may set limits on mercury levels in fish or antibiotic levels in meat, it seems in keeping 
with its role to expect that the FDA would impose stricter regulations on sunlamps.  
 
VII. Caselaw on Consumer Use of Sunlamps 
  Several recent court cases indicate that the consumer choice rationale may be 
flawed. Two predominant types of cases have appeared in recent years: cases where the 
plaintiff argues that advertising of indoor tanning is misleading, and cases in which a 
plaintiff suffered harm from sunlamp use. Though the claims and legal arguments differ, 
the results indicate the same conclusion: consumers are not fully informed of the dangers 
sunlamps pose to their health, and the tanning industry’s efforts at consumer safety and 
information leave something to be desired.  
Several cases in the past several years have explored the possibility that the tanning 
industry distorts the risks and benefits of tanning, leaving consumers with an inadequate 
understanding of the effects of indoor tanning. In Nafar v. Hollywood Tanning, 339 
Fed.Appx. 216, 2009 WL 2386666 (C.A. (N.J.)), the plaintiff consumer claimed that 
defendant Hollywood Tanning failed to adequately represent the dangers of indoor tanning 
to her and others like her. Though Hollywood Tanning complied with FDA labeling 
regulations, Nafar claimed that the company’s employees informed her that the dangers of 
indoor tanning were minimal. Parts of the case were eventually dismissed due to choice of law and class certification issues, but the claims made by Nafar deserve closer analysis. The 
defendant here allegedly distorted the benefits of indoor tanning, promising a better 
complexion and possible treatment of skin disorders such as acne and psoriasis. Outside of 
the FDA‐required warnings, Nafar claims the defendant did not provide any information 
about the carcinogenic nature of sunlamp use, and that she would not have used Hollywood 
Tanning’s services if she had been apprised of these dangers. Though the FDA expects its 
regulations to lead to safer decisions by consumers, it seems that in Nafar’s case the 
required labels did not lead in the direction of an informed choice. Protection of consumer 
choice is premised on the conception of the consumer as reasonable person faced with all 
relevant information in making a decision; here, Nafar claims that she was deprived of the 
ability to make such a choice. 
  In In re Toshiba America HD DVD Marketing and Sales Practice Litigation, 2009 WL 
2940081, the court admitted, “the average consumer’s knowledge of the harmful effects of 
indoor tanning is a disputed issue.” While the FDA’s required warnings are meant to 
apprise the consumer of the risks of indoor tanning, it seems that there is something of a 
chasm between consumer knowledge and the knowledge of the FDA. If consumers are not 
equipped with the appropriate information to make an informed choice, should the FDA 
change labeling requirements, or does the solution lie in more restrictive usage 
requirements?  
The balance between paternalism and freedom may be difficult to strike, but if court 
cases regarding particularly egregious injuries to consumers are any indication, it may be 
time for the FDA to move in the direction of paternalism when it comes to sunlamps. In 
Swindle v. Body Blasters Gym, Inc, La.App. 2 Cir. 1999, the plaintiff’s skin turned purple after using defendant’s indoor tanning facilities. The plaintiff had been taking medication 
that made her skin more sensitive to UV light, and she blamed the extreme results she 
experienced on the defendant’s company’s negligent failure to warn her of the possibility 
that certain medications intensify the effects of indoor tanning. The court found that the 
FDA‐required warning labels had been present at the gym during her use of the facilities, 
and dismissed her case. Of note in the Swindle case is the court’s equation of reasonable 
care with meeting the FDA’s requirements. Vendors of sunlamp services are not 
responsible for providing any more warning that that required by the FDA, and thus the 
FDA’s regulations take on a great deal of importance for consumer safety. The FDA’s role in 
essentially defining the negligence standard for sunlamp operators means that its required 
labels are the only protection consumers can expect.  
In Faranso v. Cass Lake Beach Club, Inc., Mich.App. 1998 WL 1991226, the plaintiff 
sustained severe sunburns when she fell asleep in a tanning bed and awoke over an hour 
later. She sued defendant Cass Lake Beach Club for negligence in operating their facilities, 
but lost the case because she signed a waiver of liability that the court found valid. Ms. 
Faranso read and signed a sheet of paper indicating that she would not hold the defendant 
liable for any damages from using their tanning beds. The court found that since Ms. 
Faranso was not incapacitated in any way when she signed the waiver, it was valid and 
Cass Lake Beach Club was not liable for her injuries. The Faranso case shows that courts 
expect consumers to inform themselves of the dangers of sunlamp use and in addition to 
making the decision whether to use sunlamps courts expect that consumers can reasonably 
decide whether to sign a liability waiver. Liability waivers are common in many industries, 
and given that sunlamps pose health dangers to their users, it makes sense that operators of indoor tanning facilities would pursue this avenue to protect themselves from liability. In 
fact, the relative dearth of cases regarding indoor tanning injuries despite the statistics on 
actual injuries sustained in the United States as a result of their use may be related to the 
use of such waivers by operators of tanning facilities.  
Claims of misinformation, negligence, and mistake appear in the above cases, and 
they demonstrate some serious problems with the consumer choice justification offered by 
the FDA in its regulation of sunlamps.  It could be argued that despite adequate warnings, 
some consumers will make the choice to use sunlamps for cosmetic purposes. Be that as it 
may, the question then arises whether the FDA’s role should be limited to sharing 
information about the dangers and providing for minimal safety standards, or whether it is 
time for more aggressive measures.  
 
Conclusion 
  FDA regulation of sunlamps since 1974 has left the cost‐benefit analysis regarding 
their use to the consumer. Aside from a few nonintrusive usage requirements, the FDA has 
focused almost exclusively on informing the consumer about the dangers of indoor tanning 
and leaving the decision to consumer discretion. Given the increasing popularity of 
sunlamp use, the skyrocketing rates of skin cancer in the United States, and expressions of 
consumer dismay when they are in fact injured by sunlamp use, it is safe to say that the 
FDA’s efforts to inform consumers have not been successful to date. State efforts to protect 
minors appear to work, but these efforts have been based on a paternalistic rationale it 
would be difficult to extend to adult consumers. PPACA’s tanning tax may be an 
intermediate solution to the difficulty of regulating sunlamp use while ensuring consumer choice. By nudging consumers in the proper direction, the tax may reduce some consumers’ 
usage of sunlamps while ultimately leaving the cost‐benefit analysis in the hands of 
consumers. As a relatively new tax, the effects of PPACA’s  tanning tax are not yet known, 
but it does seem to be a step in the right direction. 
  Despite the existence of several options for regulating sunlamp use, injuries from 
sunlamp use and the dangers of UV exposure dictate that the FDA should reconsider its 
support of consumer choice and get more involved in protecting consumers from the 
dangers of sunlamp use. At the very least, reclassification of sunlamps as a Class II Medical 
Device, subjecting them to more rigorous examination and regulation by the FDA, appears 
to be called for. Reclassification would continue to provide consumers with the choice of 
whether to engage in indoor tanning while hopefully serving to explore whether there is 
any way to reduce the risks that consumers face. Such action by the FDA would respect the 
autonomy of consumers while enabling regulators to get more involved in demanding more 
from the tanning industry.  